Dr. Vince Clinical Research Strengthens Obesity CRO Credentials as Principal Investigator Earns ABOM Board Certification

• Dr. Vince Clinical Research (DVCR), a full-service early phase CRO based in Overland Park, Kansas, has announced that Principal Investigator William Lavery, MD, PhD, is now certified by the American Board of Obesity Medicine (ABOM), adding specialist clinical credentialing to the CRO’s growing obesity and metabolic drug development capabilities.

• The certification deepens DVCR’s clinical bench at a time of significant sponsor investment in obesity pharmacotherapy, including programs targeting GLP-1 receptor agonists, oral agents, and combination metabolic strategies requiring early phase CRO partners with both specialized investigator expertise and established patient recruitment infrastructure.

Dr. Vince Clinical Research (DVCR), a full-service contract research organization specializing in early phase clinical development, announced on June 3, 2026, from Overland Park, Kansas, that Principal Investigator William Lavery, MD, PhD, has earned board certification from the American Board of Obesity Medicine. The milestone adds obesity medicine specialist credentialing to DVCR’s early phase CRO capabilities in an area of sustained and growing sponsor focus, as obesity and its co-morbid conditions continue to drive significant activity across both the pharmaceutical pipeline and the broader clinical research landscape.

Dr. Lavery, who previously held board certification in Allergy and Immunology and has participated in over 75 clinical trials as a Principal Investigator or Sub-Investigator, joins a clinical team at DVCR that includes Dr. George Atiee, who brings over 35 years of clinical research experience and a broad history across early phase CRO operations. The addition of formal obesity medicine credentialing to Dr. Lavery’s profile reinforces DVCR’s positioning as an early phase CRO with clinically qualified investigators capable of overseeing complex cardiometabolic studies in both healthy volunteer and patient populations.

The announcement reflects the strategic priority DVCR has placed on obesity and metabolic research infrastructure. The CRO operates a 100-bed clinical pharmacology unit with cGMP-compliant pharmacy capabilities, strong recruitment infrastructure for overweight, obese, and cardiometabolic disorder patient populations, and a full suite of early phase services including project management, data management, biostatistics, PK/PD analysis and modeling, clinical and medical monitoring, and medical writing. These capabilities are directly relevant to the evolving requirements of obesity drug development, where sponsors are increasingly seeking early phase CRO partners with both the clinical expertise and the operational infrastructure to execute complex Phase 1 and Phase 2a programs efficiently.

For sponsors working beyond first-generation GLP-1 receptor agonist therapies, DVCR positions its combined capabilities as relevant to programs evaluating oral agents, combination metabolic approaches, and strategies designed to improve long-term tolerability and patient adherence — areas where investigator expertise, patient population access, and early phase operational rigor are all critical to generating high-quality data ahead of later-stage development.

“Combined with Dr. Lavery’s certification, these capabilities position DVCR to deliver on the evolving needs of our Sponsors.”

Official company statement